Teva Pharma Stock Options Expiring on 21st of March

TEVA Stock  USD 22.01  0.19  0.87%   
Teva Pharma's latest option contracts expiring on March 21st 2025 are carrying combined implied volatility of 0.65 with a put-to-call open interest ratio of 0.48 over 48 outstanding agreements suggesting investors are buying more calls than puts on contracts expiring on March 21st 2025. The total put volume is at 64.0, with calls trading at the volume of 704. This yields a 0.09 put-to-call volume ratio.

Open Interest Against March 21st 2025 Option Contracts

The chart above shows Teva Pharma's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Teva Pharma's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Teva Pharma's option, there is no secondary market available for investors to trade.

Teva Pharma Maximum Pain Price Across 2025-03-21 Option Contracts

Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of particular securities such as Teva Pharma close to expiration to expire worthless. So, Max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, Teva Pharma's option sellers may reap the most after selling more options than buying, causing them to expire worthless.
Teva Pharma's stock options are financial instruments that give investors the right to buy or sell shares of Teva Pharma Industries common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Teva stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Teva Pharma's stock price goes up or down, the stock options follow.
At present, Teva Pharma's Total Stockholder Equity is projected to decrease significantly based on the last few years of reporting. The current year's Other Stockholder Equity is expected to grow to about 28.6 B, whereas Common Stock Shares Outstanding is forecasted to decline to about 777 M.

Teva Pharma Industries In The Money Call Balance

When Teva Pharma's strike price is surpassing the current stock price, the option contract against Teva Pharma Industries stock is said to be in the money. When it comes to buying Teva Pharma's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Teva Pharma Industries are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

Teva Current Options Market Mood

Teva Pharma's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Teva Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Open Interest

Put-to-Call Volume

Most options investors, including buyers and sellers of Teva Pharma's calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. Teva Pharma's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.

Rule 16 of the current Teva contract

Base on the Rule 16, the options market is currently suggesting that Teva Pharma Industries will have an average daily up or down price movement of about 0.0406% per day over the life of the 2025-03-21 option contract. With Teva Pharma trading at USD 22.01, that is roughly USD 0.008942. If you think that the market is fully incorporating Teva Pharma's daily price movement you should consider buying Teva Pharma Industries options at the current volatility level of 0.65%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
  

Teva Pharma Option Chain

When Teva Pharma's strike price is surpassing the current stock price, the option contract against Teva Pharma Industries stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Teva Pharma's option chain is a display of a range of information that helps investors for ways to trade options on Teva. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Teva. It also shows strike prices and maturity days for a Teva Pharma against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.
Open IntStrike PriceCurrent SpreadLast Price
Call
TEVA250321C0000300073.017.8 - 21.0518.92In
Call
TEVA250321C00008000128.013.85 - 15.413.7In
Call
TEVA250321C00009000229.012.9 - 13.4513.75In
Call
TEVA250321C000100006110.011.1 - 13.111.73In
Call
TEVA250321C000110001411.010.35 - 11.210.31In
Call
TEVA250321C00012000144012.010.05 - 10.29.05In
Call
TEVA250321C0001300021213.09.1 - 9.27.82In
Call
TEVA250321C000140009114.07.15 - 9.28.1In
Call
TEVA250321C00015000129315.06.8 - 8.157.05In
Call
TEVA250321C00016000117116.05.25 - 7.35.78In
Call
TEVA250321C00017000230117.05.2 - 5.35.35In
Call
TEVA250321C00018000603818.04.25 - 4.354.1In
Call
TEVA250321C000190001209819.02.83 - 3.453.35In
Call
TEVA250321C000200003551220.02.29 - 2.692.72In
Call
TEVA250321C000210001293521.01.78 - 2.121.94In
Call
TEVA250321C000220003681122.01.09 - 1.331.3Out
Call
TEVA250321C000230002131023.00.77 - 0.890.94Out
Call
TEVA250321C00024000359224.00.52 - 0.580.57Out
Call
TEVA250321C00025000215025.00.33 - 0.360.33Out
Call
TEVA250321C0002600010726.00.2 - 0.230.21Out
Call
TEVA250321C00027000210327.00.12 - 0.150.11Out
Call
TEVA250321C00028000428.00.06 - 0.10.13Out
Call
TEVA250321C000290004229.00.02 - 0.180.09Out
Call
TEVA250321C0003000041030.00.01 - 0.170.05Out
Call
TEVA250321C0003200091032.00.02 - 0.040.02Out
 Put
TEVA250321P00008000258.00.0 - 0.010.01Out
 Put
TEVA250321P000100007810.00.0 - 0.020.01Out
 Put
TEVA250321P000110001111.00.0 - 0.140.1Out
 Put
TEVA250321P00012000763412.00.0 - 0.020.02Out
 Put
TEVA250321P0001300080613.00.0 - 0.150.1Out
 Put
TEVA250321P00014000223914.00.01 - 0.160.03Out
 Put
TEVA250321P000150001163515.00.04 - 0.050.05Out
 Put
TEVA250321P00016000127816.00.04 - 0.190.07Out
 Put
TEVA250321P00017000242317.00.03 - 0.10.19Out
 Put
TEVA250321P000180002593818.00.09 - 0.150.14Out
 Put
TEVA250321P0001900087619.00.2 - 0.260.3Out
 Put
TEVA250321P00020000263320.00.29 - 0.440.43Out
 Put
TEVA250321P00021000997821.00.35 - 0.730.73Out
 Put
TEVA250321P00022000136722.01.01 - 1.151.1Out
 Put
TEVA250321P0002300011223.01.26 - 1.741.74In
 Put
TEVA250321P000240006224.02.3 - 2.643.3In
 Put
TEVA250321P0002500022125.02.42 - 4.253.25In
 Put
TEVA250321P0002600011126.04.05 - 4.153.9In
 Put
TEVA250321P0002700032127.04.95 - 6.05.3In
 Put
TEVA250321P00028000128.05.9 - 6.956.25In
 Put
TEVA250321P00029000029.06.85 - 7.86.85In
 Put
TEVA250321P00030000030.07.1 - 8.0511.75In
 Put
TEVA250321P00032000032.09.05 - 11.09.54In

Teva Pharma Selling And Marketing Expenses Over Time

   Selling And Marketing Expenses   
       Timeline  

Teva Pharma Market Cap Over Time

   Market Cap   
       Timeline  

Teva Total Stockholder Equity

Total Stockholder Equity

9.89 Billion

At present, Teva Pharma's Total Stockholder Equity is projected to decrease significantly based on the last few years of reporting.

Teva Pharma Corporate Directors

Nechemia PeresIndependent DirectorProfile
JeanMichel HalfonStatutory - independent directorProfile
Perry NisenIndependent DirectorProfile
Gerald LiebermanIndependent DirectorProfile
When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.4
Earnings Share
(0.85)
Revenue Per Share
14.879
Quarterly Revenue Growth
0.125
Return On Assets
0.0556
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.